ArticleCardiovascular diabetology2018

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

Annayya R Aroor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.